Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 15/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19851017 | 0.89 | SLC22A12 (0.53) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL19851022 | 0.87 | TSHR (0.59) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL21093644 | 0.86 | SLC22A12 (0.48) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL19851103 | 0.84 | ALDH1A1 (0.53) | CYP2C9CYP3A4CYP1A2HPGDPOLB | |
| SCHEMBL19851129 | 0.84 | SLC22A12 (0.70) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL23954463 | 0.84 | SLC22A12 (0.45) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL19851014 | 0.83 | SLC22A12 (0.76) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL19851020 | 0.83 | SLC22A12 (0.74) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL19851127 | 0.82 | SLC22A12 (0.45) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL19851132 | 0.82 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP3A4CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495362-B1 | IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | UNIV SHANDONG (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10399978-B2 | Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1 | SHANDONG UNIVERSITY (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20190225606-A1 | Novel Imidazopyridine Thioglycolic Acid Derivatives as Potent Inhibitors of Human Urate Transporter 1 | SHANDONG UNIVERSITY (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3495362-A1 | IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shandong University (CN) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018023851-A1 | IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东大学 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225606-A1 | Novel Imidazopyridine Thioglycolic Acid Derivatives as Potent Inhibitors of Human Urate Transporter 1 | SLC29A1, SLC28A1, SLC5A1 | SLC22A12 118/4885CYP2C9 292/4885CYP3A4 1101/4885 |
| US-10399978-B2 | Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1 | SLC29A1, SLC28A1, SLC5A1 | SLC22A12 163/4885CYP2C9 254/4885CYP3A4 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.